First-line toripalimab plus chemotherapy versus chemotherapy for advanced esophageal squamous cell carcinoma: A cost-effectiveness analysis

Jing-Wen Han, Yu Zhong, Jin Zhong, Wen-Jing Zeng, Li-Jun Sun

Open source

DOI
10.1371/journal.pone.0325808
Published
2025-06-10
Container
PLOS One
Publisher
Public Library of Science (PLoS)
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1371/journal.pone.0325808,
  title = {First-line toripalimab plus chemotherapy versus chemotherapy for advanced esophageal squamous cell carcinoma: A cost-effectiveness analysis},
  author = {Jing-Wen Han and Yu Zhong and Jin Zhong and Wen-Jing Zeng and Li-Jun Sun},
  year = {2025},
  journal = {PLOS One},
  doi = {10.1371/journal.pone.0325808},
  url = {https://doi.org/10.1371/journal.pone.0325808}
}

RIS

TY  - JOUR
TI  - First-line toripalimab plus chemotherapy versus chemotherapy for advanced esophageal squamous cell carcinoma: A cost-effectiveness analysis
AU  - Jing-Wen Han
AU  - Yu Zhong
AU  - Jin Zhong
AU  - Wen-Jing Zeng
AU  - Li-Jun Sun
PY  - 2025
JO  - PLOS One
DO  - 10.1371/journal.pone.0325808
UR  - https://doi.org/10.1371/journal.pone.0325808
ER  - 

APA

Han, J., Zhong, Y., Zhong, J., Zeng, W., & Sun, L. (2025). First-line toripalimab plus chemotherapy versus chemotherapy for advanced esophageal squamous cell carcinoma: A cost-effectiveness analysis. PLOS One. https://doi.org/10.1371/journal.pone.0325808

Source records